Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives

World J Gastroenterol. 2024 Apr 28;30(16):2179-2183. doi: 10.3748/wjg.v30.i16.2179.


In this editorial we comment on the article published in the recent issue of the World journal of Gastroenterology. We focus specifically on the mechanisms un-derlying the effects of fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS), the factors which affect the outcomes of FMT in IBS patients, and challenges. FMT has emerged as a efficacious intervention for clostridium difficile infection and holds promise as a therapeutic modality for IBS. The utilization of FMT in the treatment of IBS has undergone scrutiny in numerous randomized controlled trials, yielding divergent outcomes. The current frontier in this field seeks to elucidate these variations, underscore the existing knowledge gaps that necessitate exploration, and provide a guideline for successful FMT imple-mentation in IBS patients. At the same time, the application of FMT as a treatment for IBS confronts several challenges.

Keywords: Fecal microbiota transplantation; Irritable bowel syndrome; Meta-analysis; Microbiota; Randomized controlled trial.

Publication types

  • Editorial

MeSH terms

  • Clostridioides difficile / pathogenicity
  • Clostridium Infections / microbiology
  • Clostridium Infections / therapy
  • Fecal Microbiota Transplantation* / methods
  • Feces / microbiology
  • Gastrointestinal Microbiome*
  • Humans
  • Irritable Bowel Syndrome* / microbiology
  • Irritable Bowel Syndrome* / therapy
  • Randomized Controlled Trials as Topic
  • Treatment Outcome